You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Fluorescent Lateral Flow Assay for Diagnosis of Cocciodioidomycosis

    SBC: Immuno-mycologics, Inc.            Topic: N/A

    Coccidioidomycosis, also known as Valley Fever, is a disease caused by inhalation of Coccidioides arthroconidia. This disease is endemic to the southwestern United States, parts of Mexico, and Central and South America. Every year approximately 150,000 people in the United States become infected with Coccidioides spp. Importantly, the rate of Valley Fever cases is increasing dramatically, earni ...

    SBIR Phase I 2014 Department of Health and Human ServicesCenters for Disease Control and Prevention
  2. Antibody Secreting Cells (ASC) in Human Clostridium Difficile Infection, Colonization, and Reoccurrence

    SBC: MICROBPLEX, INC.            Topic: N/A

    Clostridium difficile infection (CDI) is a common nosocomial pathogen that plagues patients because of it relatively high rate of recurrence. Although diagnosis for primary CDI is very sensitive, there are not tests to predict recurrence. Recent human clinical trials show monocolonal antibodies to toxin A & B are protective for recurrent disease and some natural history studies suggest generation ...

    SBIR Phase I 2014 Department of Health and Human ServicesCenters for Disease Control and Prevention
  3. Tough Talks: A Disclosure Intervention for HIV+ YMSM

    SBC: VIRTUALLY BETTER INC            Topic: 105

    DESCRIPTION Surveillance estimates indicate an alarming resurgence of new HIV AIDS cases among young men who have sex with men YMSM highlighting the importance of re examining prevention modalities and behavior change strategies After diagnosis persons living with HIV continue to engage in sexual and drug use behaviors that increase the risk for transmission of HIV By continuing to engage i ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. An HIV Vaccine Strategy Based on Priming with rVSV Expressing FLSC

    SBC: PROFECTUS BIOSCIENCES, INC.            Topic: R

    DESCRIPTION Based on the prevailing evidence we believe that a highly effective vaccine for HIV prophylaxis must induce long lasting broadly cross reactive antibody responses to envelope that exhibit antiviral activity as well as multi antigen polyfunctional CD and CD T cell responses that produce antiviral chemokines and cytokines and are possibly biased towards an effector memory phenot ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Targeting endogenous sialidases for treatment of endotoxic shock

    SBC: Oncoimmune Inc            Topic: NIAID

    DESCRIPTION provided by applicant Despite the advance of antibiotics sepsis remains a major challenge to human health as both survival and incidence of severe sepsis have been largely unchanged in the last two decades It is therefore important to develop new therapeutic approaches We have recently reported that bacterial sialidases may serve as therapeutic targets for polybacterial sepsis H ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Long-term anti-angiogenic activity of intravitreal ellipsoid particles for NVAMD

    SBC: Asclepix Therapeutics, Inc.            Topic: N

    DESCRIPTION provided by applicant Long term anti angiogenic activity of intravitreal ellipsoid particles for NVAMD Niranjan B Pandey Ph D PI Aleksander S Popel Ph D Co I Jordan J Green Ph D Co I Peter A Campochiaro M D Co I of subaward Project Summary Current therapies for wet age related macular degeneration AMD target vascular endothelial growth factors VEGFA and pla ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Development of Novel S. aureus Antibiotics with Reduced Resistance Susceptibility

    SBC: NOVALEX THERAPEUTICS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant Widespread antibiotic use has accelerated S aureus resistance to almost all marketed antibiotic classes including beta lactams fluoroquinolones macrolides aminoglycosides tetracyclines as well as the newer linezolid and daptomycin Methicillin resistant S aureus MRSA is an increasing public health threat with deaths from MRSA infections already compar ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Laser Speckle Imaging Chip for Telehealth Applications

    SBC: VASOPTIC MEDICAL, INC.            Topic: NIA

    DESCRIPTION provided by applicant There is a strong unmet need for a low cost and convenient technology that can assist researchers and healthcare personnel in gathering vascular data Such vascular imaging technology could assist in the short term clinica research on the diagnostics disease progression and effect of treatment prevention strategies ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Development of broad spectrum Hepatitis C Virus NS3/4A protease inhibitors

    SBC: NOVALEX THERAPEUTICS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant This is a collaborative proposal to develop inhibitors with reduced susceptibility to resistance and improved genotype spectrum of activity against the NS A protease of the Hepatitis C virus HCV Over three percent of the worldandapos s population is infected with the hepatitis C virus HCV Unfortunately the current best treatment is still quite challeng ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. In vivo conjugated multivalent toxoid-polysaccharide vaccine for S. aureus

    SBC: Integrated Biotherapeutics, Inc.            Topic: NIAID

    DESCRIPTION provided by applicant Staphylococcus aureus is a Gram positive human pathogen that causes a wide range of infections from skin and soft tissue infections SSTI to life threatening sepsis and pneumonia The pathogenicity of S aureus is dependent on numerous virulence factors including cell surface proteins and polysaccharides as well as secreted toxins An important group of thes ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government